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Chronic Graft-versus-Host Disease—Implementation of
the National Institutes of Health Consensus Criteria for
Clinical TrialsBased on collaborative discussions of the commu-
nity of hematopoietic cell transplant (HCT) physi-
cians, the National Institutes of Health (NIH)
Consensus Criteria for Clinical Trials in Chronic
Graft-versus-Host Disease (GVHD) established for
the first time comprehensive diagnostic, staging, and
response criteria for chronic GVHD (cGVHD). The
recommendations from this group were published in
a series of articles in this journal [1-6]. Implementation
of the criteria and follow-up research are needed to en-
sure continued progress. Therefore, representatives of
the national and international cGVHD community
met in Bethesda, MD, on March 8 and 9, 2007, to re-
port on continuing studies, identify unmet needs, and
consider future options. Here, we summarize findings
of the 2-daymeeting and the present spectrum of activ-
ities in the field of cGVHD.
DIAGNOSIS, STAGING, AND RESPONSE CRITERIA
There is considerable need to evaluate the diagno-
sis, staging, and response criteria prospectively in clini-
cal trials and retrospectively using existing databases. It
is highly likely that refinements will be needed, because
such criteria should always be considered a ‘‘work in
progress,’’ as clinical practice and treatments evolve
over time. Challenges to completion of validation stud-
ies include the large number of patients from multiple
centers required for an adequate statistical evaluation,
the protracted time frame needed for adequate observa-
tion, and funding needed to support the effort. Jagasia
et al. [7] and Arora et al. [8] have recently completed
the first single-site retrospective validation studies of
the diagnosis and staging criteria.These studies showed
a correlation of GVHD subtype (late acute versus clas-
sic chronic) and severity with overall survival (OS). At
the workshop, Jacobsohn et al [9] presented a compari-
son of the Johns Hopkins Hospital skin response crite-
ria as used in the recently published pentostatin trial
with the NIH consensus response criteria. Their data
showed that the 2 scales had similar and complemen-
tary, although not identical, properties. Mitchell et al.
[10] have performed a small assessment of feasibility
and reproducibility of the NIH response criteria in
a prospective study conducted at multiple sites in theUnited States. A large prospective cohort investigation
has recently received NIH funding and is led by S. Lee
of the Fred Hutchinson Cancer Research Center
(FHCRC). A validation project is currently underway
led by D. Wolff and the German/European Union
(EU) collaborative group [11].
ORGAN-SPECIFIC RESEARCH AND ANCILLARY AND
SUPPORTIVE CARE
Because the multiple-organ clinical manifestations
of cGVHD can persist for prolonged periods of time,
supportive care is critical in long-term management.
Because there is a profound lack of data in these areas,
most of theNIHconsensus recommendations arebased
on extrapolation of clinical results from other fields of
medicine. To conduct trials in this area it will be essen-
tial to develop organ-specific severity scales, which will
require long-term data. Research addressing organ dys-
function includes skin, pulmonary, and oral mucosal
complications and conjunctival therapeutic interven-
tion studies. The bronchiolitis obliterans syndrome
(BOS) is a rare, but devastating, complication in need
of improved diagnostic criteria and therapy [12]. Stud-
ies of oral mucosa suggest that immunologic features of
cGVHD might be quantified by immunohistochemis-
try. This type of research represents an opportunity to
study the immunologic processes of cGVHD directly
at the anatomic site of the disease [13].
BIOLOGY, BIOMARKERS, AND NEW TARGETS
Chronic GVHD is remarkable for lack of insight
into the basic biology of the disease. Because of this,
there are no validated biomarkers. Targeted drug ther-
apy has been impaired by this absence of specific im-
munologic targets. Preclinical mouse models that
approximate the full spectrum of human cGVHD are
lacking, although there are several useful models that
demonstrate selected aspects of the disease process
(reviewed by Shlomchik et al. [14] and Chu and Gress
[15]). The long duration of follow-up required to as-
sess murine cGVHD has inhibited both the develop-
ment and utilization of these models. Prior studies
using patient samples have focused mainly on379
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function within tissues affected by cGVHD. Studies to
characterize new biomarkers and confirm or refute
those suggested by smaller studies in cGVHD will re-
quire large numbers of samples linked to detailed in-
formation on the clinical course. Small studies have
suggested a role for diverse immunologic cells/soluble
factors including T cells and T cell subsets, thymic-de-
pendent and -independent pathways of T cell recov-
ery, B cells, and B cell subsets, and B cell activating
factor (BAFF) [16-19]. For example, 4 inflammatory
plasma markers and an activated B cell population
identified as potential biomarkers in cGVHDin a study
performed by the Children’s Oncology Group (COG)
will require validation in a larger population that in-
cludes adults [16,17]. Larger cooperative studies, in
particular those conducted by the EU, have included
examination of gene polymorphisms in cGVHD
[20,21], and proteomics studies [22].
GRAFT-VERSUS-LEUKEMIA (GVL) EFFECTS
Growing clinical evidence suggests a major contri-
bution of cGVHD in mediating allogeneic GVL ef-
fects. Research in this important area is lacking, and
efforts to investigate the pathophysiologic basis of
the GVL effect compared to the GVHD effect should
be pursued. Representative presentations at the work-
shop addressed preclinical models and their limita-
tions, T cell and B cell aspects of the GVL effect,
and the role of hematopoietic chimerism. The possi-
bility of a humoral component in the GVL effect, in
addition to the documented T cell contribution, was
discussed [23-27]. The relation of cGVHD bio-
markers to the GVL effect will be investigated in the
COG study of GVHD prophylaxis for children receiv-
ing allogeneic HCT for acute lymphoblastic leukemia
(see also #NCT00382109 at www.ClinicalTrials.gov).
THERAPEUTIC CLINICAL TRIALS
Regarding design of clinical trials in cGVHD in
general, the selection of short-term endpoints was em-
phasized as key, including consideration of composite
endpoints. Challenges to endpoint design include lack
of validated short-term predictors (\6 months) of the
more long-term outcomes (years) of the natural history
of cGVHD, as well as the obvious need for validation
studies of response criteria in cGVHD. The trajectory
of disease progression should be given more attention
when patients are enrolled in a clinical trial. For exam-
ple, stabilization of disease manifestations could be
considered a benefit in a patient with rapidly progres-
sive cGVHD manifestations but not in those with
improving or stable manifestations before an interven-
tion. Biologic markers that could be used as short-term
predictors of therapeutic benefit would be especiallyhelpful for early drug development trials in cGVHD.
Results from recent relatively small phase II studies
suggestive of benefit from extracorporeal photophere-
sis (ECP) and Rituximab (humanized anti-CD20) for
the treatment cGVHD were presented [28,29]. Multi-
center studies of mycophenolate mofetil (MMF) and
its enteric coated formulation as an adjunct to standard
front line cGVHD therapy are currently underway in
the United States led by P. Martin at FHCRC (see
also #NCT00089141 at www.ClinicalTrials.gov) and
in Europe led by G. Socie (#NCT00298324 at
www.ClinicalTrials.gov), respectively.
RESOURCES—TRANSPLANT NETWORKS AND CLINICAL
TRIALS CONSORTIA
The total number of patients with cGVHD is
small, so that cGVHD qualifies as a ‘‘rare disease,’’
even though as many as half of all patients undergoing
allogeneicHSCT experience this complication. Coop-
erative clinical studies in cGVHD will be needed to
accomplish progress in the field. There is a corre-
sponding need to identify the type of infrastructure
that will best facilitate such multicenter projects.
Both national and international clinical collaborations
should be strongly encouraged. In the United States, 1
or more existing networks, for example, the Blood and
Marrow Transplant Clinical Trials Network (BMT
CTN), may be well positioned to provide the type of
infrastructure needed. In the recent ‘‘BMTCTNState
of the Science Symposium’’ [30], cGVHD was identi-
fied as an area of immediate need for both intensive
studies of disease mechanisms as well as therapeutic
clinical trials. A proposal for a prospective multicenter
clinical trial in cGVHD that would be coupled with
immunologic ancillary studies is currently in develop-
ment by the consortium. The Pediatric Blood and
Marrow Transplant Consortium (PBMTC), which is
a member of the BMTCTN, is an important resource
for study of aspects of cGVHD. The database of the
Center for International Blood and Marrow Trans-
plant Research (CIBMTR), which contains informa-
tion on over 240,000 HCT procedures performed
worldwide, serves as a unique and perhaps insuffi-
ciently utilized resource available for retrospective
analyses in HCT including cGVHD. Practical aspects
of International collaborations were discussed at the
workshop by representatives of the European Group
for Blood and Marrow Transplantation (EBMT), the
BMT CTN, and the National Cancer Institute
(NCI) Cancer Therapy Evaluation Program (CTEP).
RESOURCES—INVESTIGATOR INITIATED RESEARCH
Availability of funding support for studies in
cGVHD has been extremely limited. The standard
NIH Research Project (R01) format may not be
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ticenter or interdisciplinary clinical trials design. For
cGVHD in particular, the relatively small number of
cases, with lack of clear assignment of responsibility
to a singleNIH Institute/Center (IC) presents an addi-
tional challenge in applying for and successfully obtain-
ing NIH funding. However, even in this era of relative
fiscal constraint for the NIH, using the National Insti-
tute of Allergy and Infectious Diseases (NIAID) as an
example, over half of the annual budget of the Division
of Allergy, Immunology and Transplantation (DAIT)
remains available for investigator-initiated research,
representing a significant opportunity [31]. It may be
reasonable to consider cooperation of NIH ICs having
a direct or partial interest in cGVHD studies, or sup-
port through existing networks or other consortia,
when developing a funding plan for large cooperative
clinical trials. A Program Project (P01) approach may
be appropriate. Interactive discussions with U.S.
Government funding agencies should be pursued, to
promote intramural and extramural NIH and govern-
ment-wide collaborations where feasible. Investigators
should approachNIH ICswith their proposals for joint
ventures. It is likely that the NIH would view collabo-
rative efforts that result in elimination of redundant
funding or cost saving as advantageous. Opportunities
for funding other than NIH should be considered,
including other U.S. Government agencies, such as,
for example, the Food and Drug Administration
(FDA) Office of Orphan Products Development, as
well as private foundations such as the Biomarkers
Consortium of the Foundation for the NIH, and
others.
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